Loading clinical trials...
Loading clinical trials...
Safety and Efficacy of a Therapy With Cladribine Following a Treatment With Anti CD20 Compounds in Relapsing Multiple Sclerosis Patients: a Pilot Study
Conditions
Interventions
Cladribine Oral Tablet
Rituximab
+1 more
Locations
1
Switzerland
Neurocenter of Southern Switzerland, Ospedale Regionale di Lugano
Lugano, Canton Ticino, Switzerland
Start Date
December 17, 2020
Primary Completion Date
October 31, 2022
Completion Date
October 31, 2022
Last Updated
March 23, 2022
NCT07225504
NCT06276634
NCT06809192
NCT05359653
NCT07426991
NCT07376772
Lead Sponsor
Claudio Gobbi
Collaborators
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions